← Back to Clinical Trials
Recruiting NCT05336240

NCT05336240 PCOM2 - The Physician Communication Intervention, Version 2.0

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05336240
Status Recruiting
Phase
Sponsor University of Colorado, Denver
Condition HPV Infection
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2023-11-15
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 9 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Physician Communication 2 Virtual (PCOM2-virtual)Physician Communication Standard (PCOM-standard)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2023-11-15 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, was found to be effective for increasing adolescent HPV vaccination in primary care, its dissemination is limited by the need for significant research team involvement to teach providers how to use the intervention's components. To address this, investigators propose to develop and test a virtual version of PCOM, use mixed methods to assess contextual factors affecting its use compared to the original PCOM intervention, and develop an optimized version of PCOM for broad dissemination to increase adolescent HPV vaccination nationally.

Eligibility Criteria

Inclusion Criteria: * Parents: Have an adolescent between the ages of 9-17 years old and receiving adolescent care at an enrolled clinic * Providers: All providers at participating study practices will be eligible to participate. Exclusion Criteria: * Parents: Does not have an adolescent between the ages of 9-17 years old and is not receiving adolescent care at an enrolled clinic * Providers: Providers who are not at participating study practices

Contact & Investigator

Central Contact

Christine Spina, MSPH

✉ CHRISTINE.BABBEL@CUANSCHUTZ.EDU

📞 303.724.0906

Principal Investigator

Sean O'Leary, MD, MPH

PRINCIPAL INVESTIGATOR

University of Colorado, Denver

Frequently Asked Questions

Who can join the NCT05336240 clinical trial?

This trial is open to participants of all sexes, aged 9 Years or older, up to 17 Years, studying HPV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05336240 currently recruiting?

Yes, NCT05336240 is actively recruiting participants. Contact the research team at CHRISTINE.BABBEL@CUANSCHUTZ.EDU for enrollment information.

Where is the NCT05336240 trial being conducted?

This trial is being conducted at Aurora, United States, Wichita, United States.

Who is sponsoring the NCT05336240 clinical trial?

NCT05336240 is sponsored by University of Colorado, Denver. The principal investigator is Sean O'Leary, MD, MPH at University of Colorado, Denver. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology